2020
DOI: 10.1089/heq.2020.0021
|View full text |Cite
|
Sign up to set email alerts
|

Disparities in the Epidemiology of Anal Cancer: A Cross-Sectional Time Series

Abstract: Purpose: To assess the trends and sociodemographic disparities of anal cancer. Methods: For this time series, billing claims were reviewed for all encounters between 2007 and 2011 in the Yale New Haven Health System. Results: There were 80 new cases identified. Decreasing trends were seen in women and increasing trend in men (À30.1% and 27.3%). Diagnoses were more common in areas with the highest proportion of racial minorities (incidence rate ratio [IRR] = 1.75; p £ 0.01) and poverty (IRR = 1.72; p = 0.04). C… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 16 publications
0
3
0
Order By: Relevance
“…However, 30-40% of patients with advanced SCCA experience local recurrence or treatment-related toxicity ( 4 , 5 ). Despite the use of HPV vaccines, the incidence and morbidity of SCCA continue to rise ( 6 ). Anal dysplasia is poorly understood and has been more difficult to detect than lower genital tract dysplasia.…”
Section: Introductionmentioning
confidence: 99%
“…However, 30-40% of patients with advanced SCCA experience local recurrence or treatment-related toxicity ( 4 , 5 ). Despite the use of HPV vaccines, the incidence and morbidity of SCCA continue to rise ( 6 ). Anal dysplasia is poorly understood and has been more difficult to detect than lower genital tract dysplasia.…”
Section: Introductionmentioning
confidence: 99%
“…[3][4][5][6][7] Despite the use of HPV vaccines, the incidence and morbidity from SCCA continue to rise. 8 The human microbiome influences the onset and treatment response of many malignancies, including gastrointestinal cancers, [9][10][11] through the modulation of inflammation, cell proliferation, and metabolism. 12,13 Clinical and preclinical data suggest that gut microbiota can directly and indirectly modulate therapy response and toxicity.…”
Section: Introductionmentioning
confidence: 99%
“…[3][4][5][6][7] Despite the use of HPV vaccines, the incidence and morbidity from SCCA continue to rise. 8 The human microbiome influences the oncogenesis and treatment response of many cancers, including gastrointestinal cancers, [9][10][11] through the modulation of inflammation, cell proliferation, and metabolism. 12,13 Clinical and preclinical data suggest that gut microbiota are direct modulators of therapy response and toxicity.…”
Section: Introductionmentioning
confidence: 99%